Taigen Biopharmaceuticals Holdings Ltd (4157) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Taigen Biopharmaceuticals Holdings Ltd TWD 1.40, price TWD 8.85, upside -84.2%, quality 73 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Taigen Biopharmaceuticals Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 7.52 TWD – 25.55 TWD · fair‑value band 0.8600 TWD – 1.75 TWD · the 8.85 TWD price screens above the 1.40 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Taigen Biopharmaceuticals Holdings in your weekly email
Every Wednesday you see whether Taigen Biopharmaceuticals Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections.
Show more
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.
Stock analysis
Taigen Biopharmaceuticals Holdings Ltd (4157) currently trades at 8.85 TWD, while our model-based Fair Value estimate is 1.40 TWD, implying the stock looks roughly 532.1% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 2.95 TWD per share, and 0 of the 24 models we run sit above the 8.85 TWD price.
Bear case: the Growth DCF group reads lowest at 0.6600 TWD, and 24 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.8600 TWD (bear) to 1.75 TWD (bull), the price of 8.85 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Taigen Biopharmaceuticals Holdings Ltd reported revenue of 259M TWD in FY2025 versus 1.3B TWD in FY2021, a compound −33.1%/yr. Reported net income was 45.2M TWD in FY2025, compounding −50.9%/yr from FY2021.
Key figures
Market cap 6.3B TWD (≈ $198M) · P/E ratio 147.5 · P/S ratio 25.7 · EPS (TTM) 0.0600 TWD · Net margin 17.4% · Return on equity 5.1% · Return on assets (EBIT) 4.7% · Operating margin −341%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −84%, 4157 screens richer than that median.
Fair Value models
Bear 0.8600 TWDFair Value 1.40 TWDBull 1.75 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0441 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+72.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.8%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.0%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−43.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−43.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1,724% → 27%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+75.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +72.4% a year for the price.
Compare Taigen Biopharmaceuticals Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside−84% · Bottom 25%
Profitability
Return on equity (TTM)5% · Above median
Return on assets4% · Top 25%
Net margin (TTM)21% · Top 25%
Growth and dividend
Revenue growth−5% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)147.5× · Priciest 25%
P/B5.86× · Priciest 25%
P/S (TTM)24.33× · Priciest 25%
P/FCF12.1× · Pricier than median
EV/EBITDA78.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)20· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Taigen Biopharmaceuticals Holdings Ltd (4157) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.40 TWD versus a price of 8.85 TWD, about −84% upside (overvalued).
What is the fair value of 4157?
Our model-based fair value for Taigen Biopharmaceuticals Holdings Ltd is 1.40 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 8.85 TWD.
What is the quality score of 4157?
Taigen Biopharmaceuticals Holdings Ltd has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Taigen Biopharmaceuticals Holdings Ltd (4157)?
Our model-based price target is the fair value of 1.40 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 0.8600 TWD, optimistic scenario 1.75 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Taigen Biopharmaceuticals Holdings Ltd stock forecast for 2026?
Our models put fair value at 1.40 TWD, about −84% upside versus a price of 8.85 TWD (overvalued). Cautious scenario 0.8600 TWD, optimistic scenario 1.75 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Taigen Biopharmaceuticals Holdings Ltd (4157)?
Taigen Biopharmaceuticals Holdings Ltd reported trailing-twelve-month revenue of about 259M TWD (latest available figure, as of Sep 24, 2026).
What growth is priced into Taigen Biopharmaceuticals Holdings Ltd (4157)?
For today's price to be fair in a discounted-cash-flow model, Taigen Biopharmaceuticals Holdings Ltd would have to grow free cash flow by +75.1 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +61.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 4157 use?
Our models discount Taigen Biopharmaceuticals Holdings Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.19, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Taigen Biopharmaceuticals Holdings Ltd that is +75.1 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Taigen Biopharmaceuticals Holdings Ltd (4157) delivered so far?
Over the past 5 years revenue at Taigen Biopharmaceuticals Holdings Ltd grew +61.8 % a year. The price currently implies +75.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Taigen Biopharmaceuticals Holdings Ltd (4157) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Taigen Biopharmaceuticals Holdings Ltd (+75.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Taigen Biopharmaceuticals Holdings Ltd (4157)?
The free-cash-flow yield on the price is 0.26 %: that much free cash flow Taigen Biopharmaceuticals Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Taigen Biopharmaceuticals Holdings Ltd (4157)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Taigen Biopharmaceuticals Holdings Ltd it is 1.40 TWD per share (as of Sep 24, 2026), against a price of 8.85 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Taigen Biopharmaceuticals Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4157 trades above its calculated fair value: price 8.85 TWD, fair value 1.40 TWD, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4157?
No. The price is what the market pays today (8.85 TWD); the fair value is what the company's own numbers justify (1.40 TWD). For Taigen Biopharmaceuticals Holdings Ltd the two are 7.45 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Taigen Biopharmaceuticals Holdings Ltd worth?
The market values Taigen Biopharmaceuticals Holdings Ltd at about 6.3B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 8.85 TWD; our models calculate a fair value of 1.40 TWD per share.
What do the bullish and bearish scenarios say about 4157?
Our models span a range for Taigen Biopharmaceuticals Holdings Ltd: cautious scenario 0.8600 TWD, base 1.40 TWD, optimistic 1.75 TWD per share (as of Sep 24, 2026, price 8.85 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4157?
Taigen Biopharmaceuticals Holdings Ltd trades at a price-to-earnings ratio of 147.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.40 TWD is built from several models across several years. Other multiples: P/B 5.9, P/S 24.3, EV/EBITDA 78.4.
How solid is the balance sheet of Taigen Biopharmaceuticals Holdings Ltd (4157)?
Balance-sheet figures for Taigen Biopharmaceuticals Holdings Ltd (as of Sep 24, 2026): return on equity 5.1%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is 4157 from its 52-week high?
Taigen Biopharmaceuticals Holdings Ltd trades at 8.85 TWD, about 43% below its 52-week high of 15.60 TWD and 9% above the low of 8.10 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.40 TWD is for.
Which stocks are comparable to Taigen Biopharmaceuticals Holdings Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Taigen Biopharmaceuticals Holdings Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 8.85 TWD, calculated fair value 1.40 TWD (−84%), Quality Score 73/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4157 calculated?
We run Taigen Biopharmaceuticals Holdings Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.40 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Taigen Biopharmaceuticals Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Taigen Biopharmaceuticals Holdings Ltd (4157)?
The closing price on Sep 24, 2026 was 8.85 TWD. Our model-based fair value is 1.40 TWD, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Taigen Biopharmaceuticals Holdings Ltd right now?
A high-quality business (quality 73/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (1.75 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.8600 TWD to 1.75 TWD) leaves room in how you read the outcome.
Key figures of Taigen Biopharmaceuticals Holdings Ltd
How large is the market capitalisation of Taigen Biopharmaceuticals Holdings Ltd (4157)?
The market capitalisation of Taigen Biopharmaceuticals Holdings Ltd is 6.3B TWD (≈ $198M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Taigen Biopharmaceuticals Holdings Ltd (4157)?
The price-to-sales ratio of Taigen Biopharmaceuticals Holdings Ltd is 25.7 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Taigen Biopharmaceuticals Holdings Ltd (4157)?
Earnings per share at Taigen Biopharmaceuticals Holdings Ltd are 0.0600 TWD (price ÷ EPS = P/E 147.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Taigen Biopharmaceuticals Holdings Ltd (4157)?
The net margin of Taigen Biopharmaceuticals Holdings Ltd is 17.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Taigen Biopharmaceuticals Holdings Ltd (4157)?
The return on equity (ROE) of Taigen Biopharmaceuticals Holdings Ltd is 5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Taigen Biopharmaceuticals Holdings Ltd (4157)?
On an EBIT basis the return on assets of Taigen Biopharmaceuticals Holdings Ltd is 4.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Taigen Biopharmaceuticals Holdings Ltd (4157)?
The operating margin of Taigen Biopharmaceuticals Holdings Ltd is −341% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Taigen Biopharmaceuticals Holdings Ltd (4157)?
Revenue at Taigen Biopharmaceuticals Holdings Ltd is growing −5.0% versus a year earlier (3y avg +92.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Taigen Biopharmaceuticals Holdings Ltd (4157)?
Earnings per share at Taigen Biopharmaceuticals Holdings Ltd are growing +795% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Taigen Biopharmaceuticals Holdings Ltd (4157) hold?
Taigen Biopharmaceuticals Holdings Ltd holds more cash than debt, 300M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Taigen Biopharmaceuticals Holdings Ltd in the live analysis
One click puts Taigen Biopharmaceuticals Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
